Exosome for stimulating T cell and pharmaceutical use thereof

Patent metadata

Field	Value
Publication number	US-12215136-B2
Application number	US-202318295631-A
Country	US
Kind code	B2
Filing date	Apr 4, 2023
Priority date	Dec 2, 2016
Publication date	Feb 4, 2025
Grant date	Feb 4, 2025

Abstract

The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.

First claim

What is claimed is:

1. An exosome which expresses a human leukocyte antigen (HLA), CD32, CD80, CD83, and 4-1BBL.

2. The exosome of claim 1 , wherein the exosome is derived from artificial antigen-presenting cells prepared by introducing nucleic acids encoding HLA, CD32, CD80, CD83, and 4-1BBL into cells which do not express HLA Class I and II molecules.

3. The exosome of claim 2 , wherein the cells which do not express HLA Class I and II molecules are any one of K562 cells and modified 293T cells.

4. The exosome of claim 2 , wherein the nucleic acid is inserted into a viral vector and delivered into cells.

5. The exosome of claim 2 , wherein the nucleic acid encoding HLA is as set forth in SEQ ID NO: 1.

6. The exosome of claim 2 , wherein the nucleic acid encoding CD80 is as set forth in SEQ ID NO: 2.

7. The exosome of claim 2 , wherein the nucleic acid encoding CD83 is as set forth in SEQ ID NO: 3.

8. The exosome of claim 2 , wherein the nucleic acid encoding 4-1BBL is as set forth in SEQ ID NO: 4.

9. The exosome of claim 1 , wherein the exosome further expresses one or more selected from the group consisting of CD40L, CD70, and OX40L.

10. The exosome of claim 1 , wherein the exosome is sensitized with one or more antigens selected from the group consisting of a tumor antigen, a pathogen antigen, and an autoantibody.

Assignees

• Catholic Univ Korea Ind Academic Cooperation Foundation
• The Catholic Univ Of Korea Industry—Academic Cooperation Foundation

Inventors

• Kim Tai Gyu
• Sohn Hyun Jung
• Kim Su Eon

Classifications

• A61K40/4272

  Melan-A/MART · CPC title

• A61K40/4243

  Wilms tumor 1 [WT1] · CPC title

• A61K40/46

  Viral antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C12N2501/599

  with CD designations not provided for elsewhere · CPC title